Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer (SIOPEL6)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00652132 |
Recruitment Status :
Completed
First Posted : April 3, 2008
Last Update Posted : May 29, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as sodium thiosulfate, may protect normal cells from the side effects of chemotherapy. It is not yet known whether giving sodium thiosulfate is effective in reducing hearing damage caused by cisplatin in treating young patients with liver cancer.
PURPOSE: This randomized phase III trial is studying how well sodium thiosulfate works to decrease hearing loss caused by cisplatin in treating young patients with stage I, stage II, or stage III childhood liver cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Liver Cancer Ototoxicity | Drug: cisplatin Drug: sodium thiosulfate | Phase 3 |
OBJECTIVES:
Primary
- To assess the efficacy of sodium thiosulfate (STS) to reduce the hearing impairment caused by cisplatin chemotherapy.
Secondary
- To carefully monitor any potential impact of STS on response to cisplatin and survival.
- To assess the short- and long-term tolerability of the combination of STS and cisplatin
- To prospectively evaluate and validate biological, radiological and pathological features of standard-risk hepatoblastoma for future risk adapted management
- To investigate the effect of STS on the formation of cisplatin-DNA adducts.
- To prospectively collect patient DNA specifically for the analysis of possible genetic factors that may contribute to the development of treatment-related ototoxicity and nephrotoxicity
OUTLINE: This is a multicenter study. Patients are stratified according to country, median age (< 15 months vs ≥ 15 months), and PRETEXT tumor classification (I vs II vs III). Patients are randomized to 1 of 2 treatment arms.
- Arm I (Neoadjuvant and adjuvant cisplatin): Patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (Neoadjuvant and adjuvant cisplatin and sodium thiosulphate): Patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo blood collection and tumor biopsies periodically for biological and pharmacological studies consisting of biomarker analysis, gene expression profiling, IHC, proteomic analysis, and gene rearrangement analysis. Patients undergo auditory evaluations at baseline, and at the completion of study treatment or at an age of at least 3.5 years to measure ototoxicity and hearing impairment.
After completion of study treatment, patients are followed periodically for at least 5 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 116 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multi-centre Open-label Randomised Phase III Trial of the Efficacy of Sodium Thiosulphate in Reducing Ototoxicity in Patients Receiving Cisplatin Chemotherapy for Standard Risk Hepatoblastoma |
Actual Study Start Date : | December 15, 2007 |
Actual Primary Completion Date : | September 4, 2017 |
Actual Study Completion Date : | February 28, 2018 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Arm I (cisplatin)
Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: cisplatin |
Experimental: Arm II (cisplatin + STS)
Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: cisplatin Drug: sodium thiosulfate |
- Rate of Brock grade ≥ 1 hearing loss [ Time Frame: End of trial treatment or at an age of 3.5 years, whichever is later ]To investigate if the administration of sodium thiosulfate simultaneously with the administration of Cisplatin significantly reduces the hearing impairment
- Response to preoperative chemotherapy [ Time Frame: Following completion of preoperative chemotherapy ]
Defined as:
Complete response (CR):
no evidence of disease and normal serum AFP value (for age).
Partial response (PR):
any tumour volume shrinkage associated with a decreasing serum AFP value, > 1 log below the original measurement.
Stable disease (SD):
no tumour volume change and no change, or < 1 log fall of the serum AFP concentration.
Progressive disease (PD):
unequivocal increase in 1 or more dimensions and/or any unequivocal increase of the serum AFP concentration (three successive 1-2 weekly determinations) even without clinical (physical and/or radiological) evidence of tumour re-growth.
- Complete resection [ Time Frame: Within 2 weeks after surgery. ]Total macroscopic removal of the tumour as reported by the surgeon and pathologist. In case of any doubt the lack of residual tumour must be confirmed with imaging studies performed
- Complete remission [ Time Frame: End of trial treatment ]
Lack of evidence of residual disease and normal (for age) alpha-foetal protein (AFP). To establish a complete remission all of the following requirements must be fulfilled:
- No evidence of tumour intra-abdominally: negative abdominal (including hepatic) ultrasound or CT scan or Magnetic resonance imaging
- No evidence of metastases: clear chest X-ray (PA and lateral) for non-metastatic patients. (Normal lung CT scan for patients with lung metastasis at diagnosis, who are high-risk by definition and not treated according to SIOPEL 6).
- Serum AFP level either normal or compatible with age for at least 4 weeks after normalisation.
- Event-free survival (EFS) [ Time Frame: Until first event or up to 5 years ]Calculated from the time of randomisation to the first of the following events: progression, relapse, secondary primary malignancy or death.
- Overall survival (OS) [ Time Frame: Until event or up to 5 years ]Calculated from the time of randomisation to death.
- Toxicity as graded by CTCAE v 3.0 [ Time Frame: 30 days post treatment ]Adverse drug reactions are defined as adverse events, which are possibly, probably or definitely related to the trial treatment. They will be assessed according to NCI CTCAE v 3.0.
- Long-term renal clearance [ Time Frame: Until event or up to 5 years ]By clearance method either EDTA, iohexol or inulin.
- Feasibility of central audiology review [ Time Frame: End of trial treatment or at an age of 3.5 years, whichever is later ]The feasibility of central review
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month to 18 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Histologically confirmed newly diagnosed hepatoblastoma
- Standard risk hepatoblastoma (Pretext I,II,III)
- Age ≤ 18 years and > 1 month
- Written informed consent and national/local ethics committee and regulatory approval
- Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done
- Ability to comply with requirements for submission of material for central review
- For females of child-bearing potential, a negative pregnancy test prior to study treatment is required.
- Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial.
Exclusion:
High risk hepatoblastoma
- Hepatocellular carcinoma
- Treatment starting more than 15 days from written biopsy report
- Abnormal renal function
- Any previous chemotherapy
- Recurrent disease
- Previous hypersensitivity to STS
- Patient unable to follow the protocol for any reason
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00652132
United Kingdom | |
Birmingham Children's Hospital | |
Birmingham, England, United Kingdom, B4 6NH | |
Bristol Royal Hospital for Childre | |
Bristol, England, United Kingdom, BS2 8AE | |
Addenbrooke's Hospital | |
Cambridge, England, United Kingdom, CB2 2QQ | |
Royal Marsden - London | |
London, England, United Kingdom, SW3 6JJ | |
Great Ormond Street Hospital for Children | |
London, England, United Kingdom, WC1N 3JH | |
Royal Manchester Children's Hospital | |
Manchester, England, United Kingdom, M27 4HA | |
Queen's Medical Centre | |
Nottingham, England, United Kingdom, NG7 2UH | |
Sheffield Hallam University - City Campus | |
Sheffield, England, United Kingdom, S1 1WB | |
Royal Aberdeen Children's Hospital | |
Aberdeen, Scotland, United Kingdom, AB25 2ZG | |
Royal Hospital for Sick Children | |
Glasgow, Scotland, United Kingdom, G3 8SJ | |
The Noah's Ark Children's Hospital for Wales | |
Cardiff, United Kingdom | |
Royal Hospital For Sick Children | |
Edinburgh, United Kingdom | |
Leicester Royal Infirmary | |
Leicester, United Kingdom | |
Alder Hey Children's Hospital Trust | |
Liverpool, United Kingdom | |
John Radcliffe Hospital | |
Oxford, United Kingdom | |
Southampton Children's Hospital | |
Southampton, United Kingdom |
Principal Investigator: | Milind D. Ronghe, MD | Royal Hospital for Sick Children |
Responsible Party: | University of Birmingham |
ClinicalTrials.gov Identifier: | NCT00652132 |
Other Study ID Numbers: |
RG_09-205 CDR0000590649 ( Other Identifier: PDQ (Physician Data Query) ) 2007-002402-21 ( EudraCT Number ) SIOP-CCLG-LT-2007-03 ( Other Identifier: CCLG - previous Sponsor ) |
First Posted: | April 3, 2008 Key Record Dates |
Last Update Posted: | May 29, 2018 |
Last Verified: | May 2018 |
ototoxicity childhood hepatoblastoma stage I childhood liver cancer stage II childhood liver cancer stage III childhood liver cancer |
Liver Neoplasms Hepatoblastoma Ototoxicity Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Liver Diseases Neoplasms, Complex and Mixed Neoplasms by Histologic Type Ear Diseases Otorhinolaryngologic Diseases Pathologic Processes Drug-Related Side Effects and Adverse Reactions |
Chemically-Induced Disorders Radiation Injuries Wounds and Injuries Sodium thiosulfate Antidotes Protective Agents Physiological Effects of Drugs Antioxidants Molecular Mechanisms of Pharmacological Action Antitubercular Agents Anti-Bacterial Agents Anti-Infective Agents Chelating Agents Sequestering Agents |